Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 369 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Expanding the horizons of the life science economy May 3, 2022 ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ November 22, 2018 For Childhood Eye Cancer, Researchers Investigating “Packaged” CAR T Cells November 10, 2020 Investigating suspected prostate cancer: improving GP-patient communication October 6, 2021 Load more HOT NEWS ctDNA May Guide Who Needs Chemo After Colorectal Cancer Surgery Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with... Merging the Histologic and Molecular Data Into an Integrated Score Significantly... How I Coped With My Own Cancer Diagnoses As an Oncologist
